Mass Spectrometry-Based Human Breath Analysis: Towards COVID-19 Diagnosis and Research

Zi-Cheng Yuan · Bin Hu

Received: 26 March 2021 / Accepted: 25 June 2021 / Published online: 16 August 2021
© The Nonferrous Metals Society of China 2021

Abstract
COVID-19 is a highly contagious respiratory disease that can be infected through human exhaled breath. Human breath analysis is an attractive strategy for rapid diagnosis of COVID-19 in a non-invasive way by monitoring breath biomarkers. Mass spectrometry (MS)-based approaches offer a promising analytical platform for human breath analysis due to their high speed, specificity, sensitivity, reproducibility, and broad coverage, as well as its versatile coupling methods with different chromatographic separation, and thus can lead to a better understanding of the clinical and biochemical processes of COVID-19. Herein, we try to review the developments and applications of MS-based approaches for multidimensional analysis of COVID-19 breath samples, including metabolites, proteins, microorganisms, and elements. New features of breath sampling and analysis are highlighted. Prospects and challenges on MS-based breath analysis related to COVID-19 diagnosis and study are discussed.

Keywords COVID-19 · SARS-CoV-2 · Breath analysis · Breath sampling · Multidimensional analysis · Mass spectrometry

1 Introduction
Coronavirus disease (COVID-19) is an infectious disease can be infected through person-to-person transmission by human exhaled breath when an infected person coughing, sneezing, or exhaling [1–3]. Human exhaled breath is a kind of bioaerosol (i.e., exhaled breath aerosol, EBA) containing water, volatile organic compounds (VOCs), droplets which can dissolve various non-volatile metabolites, salts, proteins, and microorganisms such as bacterial and viral particles. EBA is a significant source of coronavirus (SARS-CoV-2) emission because EBA can suspend in the contaminated air and cause infection by respiration action [4]. Diagnosing COVID-19 now mainly depends on polymerase chain reaction (PCR) technique [5], which is highly expected to be the most reliable test for diagnosing COVID-19 by the genomic identification of SARS-CoV-2. Theoretically, the limit of PCR is a single molecule, since PCR is a molecular technology that can exponentially amplify a fragment of nucleic acid, making PCR as a powerful tool for identifying special nucleic acid sequences. During PCR testing, coronavirus should be collected from specimen swab for RNA extraction and transcription to diagnose COVID-19 [6]. Although PCR technique is effective and sensitive for diagnosing COVID-19, many limitations such as sampling quality, sample pretreatment, and tedious result time were frequently reported in practice applications. False-negative results of PCR detection drive the new development of other supportive analytical methods for diagnosing COVID-19 [6–19]. To improve the accuracy of COVID-19 diagnosis, different clinical samples such as blood, urine, feces, saliva, and breath are considered for screening viruses or/and virus-specific metabolites [20–29], which are also expected to provide new insight into the health impact of COVID-19 [30].

Mass spectrometry (MS) is a powerful analytical tool for investigating genomics, proteomics, metabolomics, and microbiomics of human diseases, due to its unique advantages including sensitivity, specificity, and speed [31–33]. MS-based technologies are powerful analytical tools to investigate COVID-19 disease [34, 35]. Different MS approaches with various sampling, separation, and ionization techniques, such as gas chromatography (GC), liquid chromatography (LC), and inductively couple plasma (ICP),
and matrix-assisted laser desorption/ionization (MALDI), can be used in omics research, biomarker discovers, qualitative and quantitative detection [36]. Particularly, ambient ionization (AI)-MS (e.g., paper spray [37]; desorption electrospray ionization, DESI) [38], and direct ionization (DI)-MS techniques (e.g., proton transfer reaction, PTR) [17], have been used for diagnosing COVID-19, and other direct ionization/sampling methods using direct sampling/ionization with medical swab [39, 40] also show potential for COVID-19 studies. Significant MS-based metabolomic and proteomic studies on COVID-19-related human body fluids have been achieved [30, 41–47].

Considering the respiratory properties of COVID-19, analyzing human EBA profiles is useful in clinical and pathologic studies on COVID-19 [48]. Breath sampling technologies combining with MS methods with great potentials have been emerged. Multifarious analytes in human breath samples can be easily introduced or collected by well-designed devices for online or offline analysis. Breath samples including exhaled breath condensate (EBC), VOCs, and EBA are commonly analyzed by MS-based approaches. A variety of MS-based methods on the advances of breath analysis have been developed, some of which have been successfully used for diagnosis and research of COVID-19. Undoubtedly, MS-based breath analysis could provide a better diagnosis and understanding of COVID-19. Thus, this paper will review and prospect the MS-based multidimensional analysis of human breath samples for diagnosis and research of COVID-19, including small organic molecules, inorganic constituents, biomacromolecules and microorganisms. The future opportunities and challenges of these MS-based methods will be discussed.

## 2 MS-Based Multidimensional Breath Analysis

Compared to other COVID-19 diagnostic techniques, MS-based multidimensional analysis of human breath samples has many advantages, including total noninvasiveness, in vivo, easy operation, good analytical performances and applicability, as summarized in Tables 1 and 2. Breath analysis has the potential of complementary of human body fluid analysis. EBC and EBA are commonly collected for MS diagnosis of various human diseases (Table 3). Particularly, metabolites, proteins, salts, and microorganisms could be exhaled from humans, and could provide abundant biological and clinical information for better understanding of COVID-19. Therefore, MS-based human breath analysis can be roughly divided into five categories according to the dimensions of analyte properties (Fig. 1): (1) DI-MS analysis of EBA using online sampling methods, (2) GC–MS analysis of volatile metabolites, (3) LC–MS analysis of non-volatile metabolites and proteins, (4) MALDI-MS analysis of proteins and microorganisms, (5) ICP-MS analysis of trace elements. These MS-based multidimensional technology

### Table 1 Different methods for diagnosing COVID-19

| Diagnostic methods                  | Samples                        | Analysis time | Cost | Performances                                                                 | References |
|-------------------------------------|--------------------------------|---------------|------|-----------------------------------------------------------------------------|------------|
| RT-PCR                              | Nasopharyngeal and throat swab, feces | 3–4 h         | High | Sensitivity: 97.2% (sputum); 62.3% (saliva); 73.3% [8]                     | [8]        |
| Loop-mediated isothermal amplification | Throat swabs                   | 30–60 min     | Medium | LOD: 118.6 copies of SARS-CoV-2 RNA per 25 μL [9]                          | [9]        |
| High-throughput automated sequencing | Oropharyngeal swab, blood, serum, plasma | 1–2 days       | High | /                                                                           | [10]       |
| Lateral flow immunoassay            | Blood, serum, plasma            | <15 min       | Low  | Sensitivity: 88.66%; specificity: 90.63% [6, 11]                            | [6, 11]    |
| Enzyme-linked immunosorbent assay   | Blood, serum, plasma            | 1–5 h         | Low  | Sensitivity: 97.1%; specificity: 97.5%; Accuracy: 97.3% [12]               | [12]       |
| Colloidal Gold-Immunochromatographic assay | Plasma                          | 10 min        | Low  | Sensitivity: 82.4%; specificity: 100% [13]                                 | [13]       |
| CRISPR-Cas12-based lateral flow assay | Nasopharyngeal or oropharyngeal swabs | ~30 min       | Low  | LOD: 10 copies/μL, Sensitivity: 90%; specificity: 100% [14]                | [14]       |
| Computed tomography scan            | Human body (lung)               | <1 h          | High | Sensitivity: ~95 to 100% [8, 15]                                           | [8, 15]    |
| Biosensor                           | Respiratory and blood samples   | ~2 h          | Low  | Sensitivity: 86.43–93.75%; specificity: 90.63–100% [16]                   | [16]       |
| Mass spectrometry                   | Breath, blood, serum, plasma, urine, nasopharyngeal and throat swab | ~5 min        | High | Accuracy: 93%, specificity: 85.7–100% [17–19]                             | [17–19]    |
platforms (Table 2) could provide a feasible avenue and comprehensive bioinformation of EBA that towards COVID-19 diagnosis and research.

### 2.1 DI-MS

The DI-MS and AI-MS analyses of EBA can be combined to one dimension here for its applicable to direct breath analysis.

---

**Table 2** MS-based approaches for diagnosis and investigation of COVID-19

| MS methods | Samples            | Analytes               | Sensitivity and specificity                                      | References |
|------------|--------------------|------------------------|-----------------------------------------------------------------|------------|
| DI-MS      | Breath             | VOCs                   | Sensitivity: 90%, accuracy: 93%, Specificity: 94% by PTR-MS      | [17]       |
|            | Nasal swabs        | SARS-CoV-2             | Diagnostic accuracy: 86.7% and 84% for DESI-MS and LD-REIMS, respectively | [38]       |
|            | Lysed cell         | Lipids                 | 93.3% correlation to the PCR classification by PS-MS            | [37]       |
| GC–MS      | Feces              | Metabolites            | COVID-19-altered fecal metabolites were correlated with clinical features, serum metabolites and gut microbes | [27]       |
|            | Breath             | VOCs                   | Sensitivity: 68%; specificity: 85.7%, positive predictive value (PPV): 89.5%, negative predictive value (NPV): 60% | [19]       |
| Blood serum| VOCs               | Sensitivity: 94%; specificity: 83% | [29]       |
| LC–MS      | Urine              | Proteins               | COVID-19 pathophysiology related molecular alterations could be detected | [20]       |
|            | Nasopharyngeal swabs| Proteins              | LOD: $9 \times 10^{-13}$ g, relationship was observed between summed MS peak intensities for SARS-CoV-2 proteins and Ct values reflecting the abundance of viral RNA | [21]       |
|            | Saliva             | Proteins               | Identifies unique peptides originating from SARS-CoV-2 nucleoprotein | [45]       |
| MALDI-MS   | Nasopharyngeal swabs| Proteins              | Sensitivity: 61.76%; accuracy: 67.66%, specificity: 71.72%      | [22]       |
|            | Plasma             | Proteins               | Sensitivity: 87.50%; accuracy: 93.10%; specificity: 100%         | [18]       |
|            | Residual nasal swab| Proteins               | Two models were identified, exhibiting accuracy of 98.3%, positive percent agreement (PPA) of 100%, negative percent agreement (NPA) of 96%, and accuracy of 96.6%, PPA of 98.5%, and NPA of 94%, respectively | [23]       |
|            | Nasal swabs        | SARS-CoV-2             | Accuracy: 93.9% with 7% false positives and 5% false negatives | [24]       |
|            | Serum              | Serum peptidome        | Sensitivity: 98%, accuracy: 99%, specificity: 100%              | [25]       |
| ICP-MS     | Blood              | Metals and metalloids  | Whole blood iron, age, and sex were determined to be independent factors associated with the disease severity, while chromium, cadmium, and the comorbidity of cardiovascular disease were determined to be independent factors associated with the mortality | [26]       |
|            | Urine              | Trace elements         | Urinary creatinine-adjusted copper of $\geq 25.57 \mu g/g$ and $\geq 99.32 \mu g/g$ were associated with significantly increased risk of severe illness and fatal outcome in COVID-19, respectively | [28]       |

**Table 3** Breath sampling methods for EBA and EBC

| Breath samples | Sampling methods                                      | References |
|----------------|-------------------------------------------------------|------------|
| EBA            | Collecting into endotracheal tube                     | [17]       |
|                | Extracting or adsorbing onto SPME fiber               | [55]       |
|                | Collecting into heated sampling tube                  | [67, 68]   |
|                | Collecting into a Mylar® bag                          | [69–71]    |
|                | Collecting into a Teflon®-bulb/Tedlar bags            | [72–74]    |
|                | Collecting into a Bio-VOC® tube                       | [75]       |
|                | Direct introducing using heated PEEK capillary        | [76]       |
| EBC            | Collecting into RTube kit (stored at $-80 \, ^\circ C$) | [78–80]    |
|                | Collecting into TURBO-DECCS collection device ($-5.5 \, ^\circ C$) | [81]       |
|                | Collecting into EcoScreen device (condensed at $-20 \, ^\circ C$, stored at $-80 \, ^\circ C$) | [82–84]    |
|                | Collecting into portable condenser at $-5 \, ^\circ C$ | [85, 86]    |
without pre-collection and preparation of breath samples. Under DI-MS analysis, EBA sample is directly introduced from human mouth into the ionization region for direct MS analysis. Several outstanding articles described the direct MS analysis of human breath samples, e.g., PTR-MS [49], selecting ion flow tube mass spectrometry (SIFT-MS) [50], extractive electrospray ionization mass spectrometry (EESI-MS) [51], secondary electrospray ionization mass spectrometry (SESI-MS) [52], and other MS techniques [53]. These DI-MS techniques are well-established methods for direct breath analysis. Due to the continuous and non-invasive introduction of gaseous breath sample, breath analysis has great clinical potential to allow direct, real-time, in vivo, and online analysis of small metabolites. These unique features of direct MS analysis make it an attractive analytical tool for rapid diagnosis of COVID-19.

Grassin-Delyle et al. [17] applied PTR-MS for detecting breath VOCs. Breath samples were directly introduced from COVID-19 patients to MS via a heated transfer line. MS data were analyzed by multivariate analysis strategy with principal component analysis (PCA) and machine-learning algorithms with different mathematical backgrounds, including orthogonal partial least-squares discriminant analysis (OPLS-DA), linear support vector machine, elastic net, and random forest (RF). PCA and OPLS-DA plots showed that breath fingerprints of COVID-19 were associated with a specific signature (Fig. 2). Some VOCs have been proposed as the biomarkers for discriminating COVID-19 and non-COVID-19 cases. This work showed that direct MS analysis of breath VOCs from patients with COVID-19 could obtain an accuracy of 93%, which might inspire to new development of online methods for large-scale COVID-19 screening.

The direct MS methods are mainly based on online breath introduction. However, the concentration of VOCs in EBA presents differences ranging from parts per million (ppm) to parts per trillion (ppt) even lower. Therefore, the concentration of VOCs in breath samples should be higher than the detection limit of MS methods. In spite of a highly efficient sample introduction, ionization, and detection in direct MS methods, many volatile biomarkers at extremely low concentrations could be undetectable. Therefore, collecting exhaled volatiles and EBC is still highly required to provide sufficient samples to extract biomarkers for offline MS analysis [54]. The collected breath samples also allow the couple with direct/ambient MS for enhanced detection of analytes from EBA. Solid-phase microextraction (SPME) technique is commonly used for VOCs sampling for MS analysis. For example, Yuan et al. [55] demonstrated the collection and enrichment of numerous breath metabolites from EBA using facemask-based microextraction technique (SPME-in-mask) followed by detection using MS with ambient ionization and GC–MS (Fig. 3). The unique feature of facemask-based SPME-MS of EBA is that the breath sampling process was separated from the MS detection in time and space. Wearable facemask sampling also is convenient for a long-time sampling even many hours in daily life, enabling enrichment of ultrarace VOCs. In addition, facemask could also protect humans from air pollutants in the ambient during the sampling process [55]. These new features have practical relevance for diagnosing COVID-19, because the breath sample is not easily handling due to their infectiousness.

2.2 GC–MS

GC–MS is a universal analytical platform, due to its excellent robustness, selectivity, sensitivity, reproducibility, separation capability, and comprehensive database [56, 57]. Exhaled breath volatiles are largely composed of inorganic volatiles such as NH$_3$, N$_2$, O$_2$, H$_2$O, CO$_2$, and trace VOCs. Breath volatiles can be originated from endogenous metabolites (generated by respiratory tract and internal organ systems and their microbiomes) and exogenous VOCs (generated by food, drugs, and environment and their metabolites). Thus, measurement of breath volatiles can gain an insight into the biochemical processes of human body. Pathogenic viruses such as COVID-19 may produce special volatiles serving as biomarkers.

Although inorganic volatiles is a main part of exhaled metabolites, however, a few studies have been conducted to assess the possible relationship between inorganic volatiles and metabolic characteristics of COVID-19. Aldhaleei et al. [58] reported a new case of hepatitis B virus reactivation caused by COVID-19, showing a higher level of ammonia (74 mmol/L) than the reference value (reference: 16–60 mmol/L). This finding could inspire measurements of exhaled inorganic volatiles using GC–MS system. VOCs are usually required to be collected into a gas bag or gas bottle for subsequently GC–MS analysis (Table 3). GC–MS analysis of breath VOC and blood metabolites has been proposed for COVID-19 diagnosis and research [29, 59–61]. To improve biomarker discovery, SPME and needle trap device
techniques were also proposed to couple with GC–MS for enhanced breath analysis in COVID-19 research [55, 61–63].

The recent emergence of portable GC–MS equipment could further improve the capability of COVID-19 diagnosis as it can be easily moved for onsite testing as needed. A Hexin portable GC–MS 2000 (weighing 19 kg with battery) can analyze breath samples within 15 min of starting up, provide a fast analysis less than 4 min (Fig. 3) and have a long continuous monitoring time over 2 h and battery standby time over 4 h. Furthermore, the availability of breath sampling, the SPME-in-mask (wearable facemask micro-extraction) [55], has been developed for direct coupling with GC–MS for breath sampling and analysis. The portable GC–MS can be programmed to monitor biomarkers for non-specialist users and allow onsite sampling and analysis. This breath analysis based on potable SPME-MS would be a huge step forward in molecular medicine. Thus, rather than shipping samples (e.g., medical swab), the portable GC–MS can be used for not only onsite sampling and analyzing of COVID-19 but also other human diseases in the community, school, hospital, etc.

### 2.3 LC–MS

EBC contains a variety of non-volatile organic compounds and biological matrices that are potential clinical sources for providing valuable biochemical information about respiratory diseases [48, 64]. Compared to EBA sampling, there are many methods for EBC sampling (Table 3). LC–MS is commonly used for analyzing organic and biological compounds and protein digestion from EBC [65, 66]. Various key factors may significantly affect the results of EBC sampling, as listed in Table 3. Unlike collecting VOCs and non-volatiles in EBA sampling under normal-temperature [17, 55, 67–76], the main factor of EBC sampling is that water vapor, metabolites, and bioparticles from exhaled samples
were condensed into a cold collector under a low temperature (below zero degrees centigrade) [77–86]. Numerous special metabolites have been studied based on LC–MS approaches. Proteins could also be biomarkers of respiratory diseases [78, 87–89]. Optimistically, LC–MS, therefore, have been proposed to COVID-19 diagnosis and research that could bring new insight into biological impact of COVID-19 [48, 60]. Various breath sampling systems (Table 3) have been successfully developed for collecting EBC [90]. Because of the low concentration of organic metabolites in EBC, further sample preparation preconcentration of breath components is usually required before LC–MS analysis. Lyophilization has been proposed as the best preconcentration option for a metabolic analysis of EBC [48].

Although breath proteins are easily collected by EBC sampling, breath proteomics analysis is difficult to investigate because of the extremely low concentration and complex biometrics. Previous studies on breath proteomics were usually conducted by protein collection, lyophilization, matrix removal, and in-solution/gel digestion before LC–MS/MS analysis [78, 87, 88]. Most experiments were performed using pooled EBC samples to improve protein detection and proteome coverage. For example, Bredberg et al. [89] applied LC–MS system to characterize protein composition of endogenous EBA from pooled samples from six (3000 L exhaled air) and ten (4400 L exhaled air) healthy donors, respectively. It was found that various proteins could be shared by blood and bronchoalveolar lavage proteins, such as albumin, serotransferrin, surfactant protein A, α1-antitrypsin, and immunoglobulins. Lacombe et al. [87] further performed LC–MS-based proteomics characterization of pooled samples of EBC. Detailed bioinformatics analysis of 153 proteins showed that most of the proteins identified corresponded to proteins secreted in the respiratory tract (e.g., lung and bronchi). A comparison study indicated that protein composition can be influenced by EBC sampling method [87]. These results revealed that EBC sampling method (Table 3) is one of the key factors for LC–MS-based proteomics and metabolomics study. A long-time and comfortable breath sampling would be beneficial to EBC collection. A facemask-based wearable microextraction device can performed breath sampling for several hours [55]. Although further studies and improvements are needed, EBC sampling coupled with LC–MS strategy may constitute a powerful tool for investigating breath proteomics and breath metabolomics of COVID-19, and thus support biomarker discovery and provide new biomedical knowledge.
2.4 MALDI-MS

Given the fact that SARS-CoV-2 can be spread through breath droplets, direct identifying SARS-CoV-2 from breath samples is highly needed [91, 92]. MALDI-MS is an effective analytical tool for identifying microorganisms, including bacteria, fungi, and viruses, for its high accuracy, mass range, and tolerance of mixtures [93–97]. Under MALDI-MS, identifying microbes is performed by matching peptide mass fingerprinting of unknown organisms or by biomarkers of unknown organisms with the protein, peptide, and nucleic acid sequence database. Human coronavirus screening using MALDI-MS can trace back to a previous work by Xiu and co-workers in 2017 [98], the time before the COVID-19 outbreak. This work established a screening platform for screening pharyngeal and/or anal swab samples collected from human patients, bats, and rodents. The results obtained by MALDI-MS showed good concordance with those results by metagenomic analysis. Recently, many outstanding studies on versatile applications of MALDI-MS for clinical diagnosis or molecular medicine research of COVID-19 have been achieved [18, 22–25]. MALDI-MS system could be used for accurately screening known coronaviruses to provide pathophysiological evidence for emerging unknown human coronaviruses. Like LC–MS analysis, a minimum amount of microbial concentration is also required for MALDI-MS identification. Due to the low concentration of virus in breath samples, collection and preconcentration (i.e., lyophilization) of EBA and EBC are also required [83, 84]. Virus-specific proteins/nucleic acids in nasopharyngeal swab samples, plasma, or serum could be analyzed by MALDI-MS. A challenging task is that MALDI-MS analysis is based on the known coronavirus sequence, which is difficult to identify a new virus. MS data analysis and process for identifying microorganisms is another challenging task. Database development, multivariate analysis, artificial intelligence, and machine learning are promising data tools for diagnosing and predicting human diseases like COVID-19.

2.5 ICP-MS

Constitution, distribution, and dynamics of trace elements in human body have increasingly become key clinical information in medicine. Trace elements could serve as biomarkers for diagnosing human disease [99]. ICP-MS is a powerful analytical technique to measure elements at trace levels in human tissues, body fluids, and exhaled breath samples for better understanding of medical conditions [99]. It is reported that severe cases of COVID-19 patients experienced an imbalance of mineral status [100, 101]. Thus, the balance of mineral status in body fluids and exhaled breath of COVID-19 patients might be significantly influenced through a yet-to-be-discovered bioinorganic mechanism. Zeng et al. [26, 28] applied ICP-MS to determine various elements, including Mn, Ca, Cr, Mn, Fe, Cu, Zn, As, Cd, Hg, Ti, Pb, and others from COVID-19 and non-severe COVID-19 patients’ body fluids. These studies revealed that significant variations of elements associated with the disease development of COVID-19 can be performed using ICP-MS.

The variation of trace elements in breath samples of COVID-19 patients is still unclear. ICP-MS characterization of trace elements in breath samples associated with COVID-19 as novel biomarkers is highly expected to better understand the underlying bioinorganic processes of COVID-19. Various previous investigations have shown that trace elements in breath samples are detectable to explore the patients’ variations using ICP-MS [85, 86]. These studies demonstrated the feasibility of ICP-MS for detecting trace elements in breath samples of COVID-19. Like other offline MS analysis, collection, and preparation of trace elements in breath samples (e.g., EBC, EBA) are usually required before ICP-MS analysis. Compared with other MS-based methods, the unique feature of ICP-MS is that COVID-19 could gain new insight at atomic dimension. Therefore, point-of-care treatment (e.g., micronutrient supplement) of COVID-19 would be a new strategy based on the elemental changes associated with the bioinorganic process in the future.

3 Conclusions and Prospects

Currently, PCR testing is still the golden standard for diagnosing COVID-19. There is still a demand to develop new methods for COVID-19 diagnosis and research. MS-based multidimensional analytical platform offers a new strategy for detecting metabolites, proteins, microorganisms, and trace elements in breath samples, which contributes important factors to develop new methods for diagnosing COVID-19 and better understanding of the underlying physiological, biochemical, and bioinorganic processes and the health impact of COVID-19. Technically, MS-based breath analysis is a practical and powerful method for investigating COVID-19 with many advantages. However, there is a lack of organized clinical resources and sufficient related literature for investigating breath samples from different dimensions.

Prospects of MS-based breath analysis are bright: (1) breath EBA sampling (e.g., facemask microextraction sampling) coupled with portable MS approaches, potable GC–MS or potable ambient MS (e.g., miniature MS [102, 103]) could provide attractive onsite diagnosis; (2) detectability of MS-based breath analysis could be further improved by a long-time breath sampling and sample preparation methods by collecting VOCs, organic metabolites, proteins, microorganisms, and elements; e.g., extracting trace compounds in daily life using facemask-related methods;
(3) combining different MS approaches (e.g., ultrasensitive and ultrahigh-resolution MS) to establish a higher dimensional MS-based platform is highly needed to extend insight to biologically and clinically relevant breath responses of COVID-19; (4) to promote deep understanding of the health impact of COVID-19, new data-dependent acquisition and data analysis methods can be expected with the new development of big data, artificial intelligence, machine learning and other mathematical methods. Together with different types of biomarkers in breath samples, the MS-based multidimensional platform of human breath analysis may be clinically useful in COVID-19 and other human diseases. Indeed, this research requires constant collaboration from different disciplines, including but not limited to analytical, instrumental, biochemical, clinical, medical, and mathematical researchers. Therefore, it can be expected that new improvements and developments of multidimensional MS-based breath analysis will bear fruits for a better diagnosis and understanding of human diseases in the future.

Acknowledgements This work was supported by the National Natural Science Foundation of China (21804053).

Declarations

Conflict of Interest The authors declare no competing financial interest.

References

1. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924.
2. Asadi S, Bouvier N, Wexler AS, Ristenpart WD. The coronavirus pandemic and aerosols: does COVID-19 transmit via exhalatory particles? Aerosol Sci Technol. 2020;54(6):635–8.
3. Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schünemann HJ, El-barakeh A, Bognanni A, Lotfi T, Loeb M. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. Lancet. 2020;395(10242):1973–87.
4. Ma J, Qi X, Chen H, Li X, Zhang Z, Wang H, Sun L, Zhang L, Guo J, Morawska L, Grinshpun SA, Biswas P, Flagan RC, Yao M. Exhaled breath is a significant source of SARS-CoV-2 and COVID-19: a systematic review with meta-analysis. Lancet. 2020;395(10242):1973–87.
5. Lahman SA, Apte S, Khan AH, Sen G, Yin D, Chaturvedi S, Thakur S, Wang J, Maffeo M, Taylor L, et al. Rapid detection of SARS-CoV-2 in clinical specimens. BioRxiv. 2020. https://doi.org/10.1101/2020.02.27.20028787.
6. Broughton JP, Deng X, Yu G, Fasching CL, Servellita V, Singh J, Miao X, Streithorst JA, Granados A, Sotomayor-Gonzalez A. CRISPR–Cas12-based detection of SARS-CoV-2. Nat Biotechnol. 2020;38(7):870–4.
7. Kovács A, Palásti P, Veréb D, Bozsik B, Pálné P, Laczkó A, Kincses ZT. The sensitivity and specificity of chest CT in the diagnosis of COVID-19. Eur Radiol. 2020;31:2819–24.
8. Lu R, Wu X, Wan Z, Li Y, Jin X, Zhang C. A novel reverse transcription loop-mediated isothermal amplification method for rapid detection of SARS-CoV-2. Int J Mol Sci. 2020;21(8):2826.
9. Grassin-Delyle S, Roquencourt C, Moine P, Saffroy G, Carn S, Heming N, Fleuriet J, Salvato C, Mallet A, et al. A rapid assay for detection of SARS-CoV-2. J Antimicrob Agents. 2020;55(3):105924.
10. Brotchi J, Alain BE, Bumbaro O, Lévy B, Li W, et al. Evaluation of current diagnostic methods for COVID-19. APL Bioeng. 2020;4(4):041506.
11. Choi J, Yi Y, Luo X, Xiong N, Liu Y, Li S, Sun R, Wang Y, Hu B, Chen W. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol. 2020;92(9):1518–24.
12. Sah R, Rodriguez-Morales AJ, Jha R, Chu DKW, Gu H, Peiris M, Bassola A, Lal BK, Ojha HC, Rabaan AA, Zambrano LI, Costello A, Morita K, Pandey BD, Poorn LLM. Complete genome sequence of a 2019 Novel Coronavirus (SARS-CoV-2) strain isolated in Nepal. Microbiol Resour Announc. 2020;9(11):e00169–20.
13. Xiang J, Yan M, Li H, Liu T, Lin C, Huang S, Chen X, Deng Q. Diagnosis of COVID-19 by exhaled breath analysis based on rapid detection of SARS-CoV-2. Front Chem. 2020;8:517.
14. Broughton JP, Deng X, Yu G, Fasching CL, Servellita V, Singh J, Miao X, Streithorst JA, Granados A, Sotomayor-Gonzalez A. CRISPR–Cas12-based detection of SARS-CoV-2. Nat Biotechnol. 2020;38(7):870–4.
learning with Maldi-Tof-Ms for rapid high-throughput screening of COVID-19: a proof of concept. Sci Rep. 2021;11:8219.

24. Nachtigall FM, Pereira A, Trofymchuk OS, Santos LS. Detection of SARS-CoV-2 in nasal swabs using MALDI-MS. Nat Biotechnol. 2020;38(10):1168–73.

25. Yan L, Yi J, Huang C, Zhang J, Fu S, Li Z, Lyu Q, Xu Y, Wang K, Yang H, Ma Q, Cui X, Qiao L, Sun W, Liao P. Rapid detection of COVID-19 using MALDI-TOP-based serum peptidome profiling. Anal Chem. 2021;93(11):4782–7.

26. Zeng HL, Yang Q, Yuan P, Wang X, Cheng L. Associations of essential and toxic metals/metalloids in whole blood with both disease severity and mortality in patients with COVID-19. FASEB J. 2021;35(3):e21392.

27. Lv L, Jiang H, Chen Y, Gu S, Xia J, Zhang H, Lu Y, Yan R, Li L. The faecal metabolome in COVID-19 patients is altered and associated with clinical features and gut microbes. Anal Chim Acta. 2021;1152:338267.

28. Zeng HL, Zhang B, Wang X, Yang Q, Cheng L. Urinary trace elements in association with disease severity and outcome in patients with COVID-19. Environ Res. 2021;194:110670.

29. Ketchanji Mougang Y, Di Zazzo L, Minieri M, Capuano R, Catini A, Legramente JM, Paolesse R, Bernardini S, Di Natale C. Sensor array and gas chromatographic detection of the blood serum volatolomic signature of COVID-19. iScience. 2021;24(8):102851.

30. Sen R. High-throughput approaches of diagnosis and therapies for COVID-19: antibody panels, proteomics and metabolomics. Future Drug Discov. 2021;3(1):FDD55.

31. Yates JR. Mass spectrometry: from genomics to proteomics. Trends Genet. 2000;16(1):5–8.

32. Griffiths WJ, Wang Y. Mass spectrometry: from proteomics to metabolomics and lipidomics. Chem Soc Rev. 2009;38(7):1882–96.

33. Swiner DJ, Jackson S, Burris BJ, Badu-Tawiah AK. Applications of mass spectrometry for clinical diagnostics: the influence of turnaround time. Anal Chem. 2019;92(1):183–202.

34. SoRelle JA, Patel K, Filkins L, Park JY. Mass Spectrometry for COVID-19. Clin Chem. 2020;66(11):1367–8.

35. Mahmud I, Garrett TJ. Mass spectrometry techniques in emerging pathogens studies: COVID-19 perspectives. J Am Soc Mass Spectrom. 2020;31(10):2013–24.

36. Hu B, Ouyang G. In situ solid phase microextraction sampling of analytes from living human objects for mass spectrometry-based analysis. TrAC Trends Anal Chem. 2021;143:116368.

37. De Silva IW, Nayek S, Singh V, Reddy J, Granger JK, Verbeck GF. Paper spray mass spectrometry utilizing Teslin® substrate for rapid detection of lipid metabolite changes during COVID-19 infection. Analyst. 2020;145(7):5725–32.

38. Ford LL, Simon D, Balog J, Jiwa N, Higginson J, Jones E, Manoli E, Mason S, Wu V, Stavrakaki S. Rapid detection of SARS-CoV2 by ambient mass spectrometry techniques. MedRxiv. 2020. https://doi.org/10.1101/2020.07.20.2007647.

39. Wu L, Yuan ZC, Li ZM, Huang Z, Hu B. In vivo solid-phase microextraction swab sampling of environmental pollutants and drugs in human body for nano-electrospray ionization mass spectrometry analysis. Anal Chim Acta. 2020;1247:71–7.

40. Wu L, Yuan ZC, Yang BC, Huang Z, Hu B. In vivo solid-phase microextraction swab mass-spectrometry for multidimensional analysis of human saliva. Anal Chim Acta. 2021;1164:338510.

41. Wu D, Shu T, Yang X, Song J-X, Zhang M, Yao C, Liu W, Huang M, Yu Y, Yang Q, Zhu T, Xu J, Mu J, Wang Y, Wang H, Tang T, Ren Y, Wu Y, Lin S-H, Qiu Y, Zhang D-Y, Shang Y, Zhou X. Plasma metabolomic and lipidomic alterations associated with COVID-19. Natl Sci Rev. 2020;7(7):1157–68.

42. Migaud M, Gandotra S, Chand HS, Gillespie MN, Thannickel VJ, Langley RJ. Metabolomics to predict antiviral drug efficacy in COVID-19. Am J Respir Cell Mol Biol. 2020;63(3):396–8.

43. Bojkova D, Klann K, Koch B, Widera M, Krause D, Ciesek S, Cinatl J, Münch C. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets. Nature. 2020;583(7816):469–72.

44. Shen B, Yi X, Sun Y, Bi X, Du J, Zhang C, Quan S, Zhang F, Sun R, Qian L, Ge W, Liu W, Liang S, Chen H, Zhang Y, Li J, Xu J, He Z, Chen B, Wang J, Yan H, Zheng Y, Wang D, Zhu J, Kong Z, Kang Z, Liang X, Ding X, Ruan G, Xiang N, Cai X, Gao H, Li L, Li S, Xiao Q, Lu T, Zhu Y, Liu H, Chen H, Guo T. Proteomic and metabolomic characterization of COVID-19 patient sera. Cell. 2020;182(1):59–72.

45. Ihling C, Tänzler D, Hagemann S, Kehlen A, Hüttelmaier S, Arlt C, Sinz A. Mass spectrometric identification of SARS-CoV-2 proteins from gargoyle solution samples of COVID-19 patients. J Proteome Res. 2020;19(11):4389–92.

46. Zhao Y, Shang Y, Ren Y, Bie Y, Qiu Y, Yuan Y, Zhao Y, Zou L, Lin S-H, Zhou X. Omics study reveals abnormal alterations of breastmilk proteins and metabolites in puerperant women with COVID-19. Signal Transduct Target Ther. 2020;5(1):247.

47. Tian W, Zhang N, Jin R, Feng Y, Wang S, Gao S, Gao R, Wu G, Tian D, Tan W, Chen Y, Gao GF, Wong CCL. Immune suppression in the early stage of COVID-19 disease. Nat Commun. 2020;11(1):5859.

48. Fernández-Peralbo MA, Calderón Santiago M, Priege-Capote F. Luque de Castro MD, Study of exhaled breath condensate sample preparation for metabolomics analysis by LC–MS/MS in high resolution mode. Talanta. 2015;144:1360–9.

49. Moser B, Bodrog F, Eibl G, Lechner M, Rieder J, Lirk P. Mass spectrometric profile of exhaled breath—field study by PTR-MS. Respir Physiol Neurobiol. 2005;145(2–3):295–300.

50. Španěl P, Smith D. Progress in SIFT-MS: breath analysis and other applications. Mass Spectrom Rev. 2011;30(2):236–67.

51. Chen H, Warnott A, Zhang W, Zenobi R. Rapid in vivo fingerprinting of nonvolatile compounds in breath by exhaustive electrospray ionization quadrupole time-of-flight mass spectrometry. Angew Chem Int Ed. 2007;46(4):580–3.

52. Singh KD, Tancev G, Decrue F, Ueemann J, Appenzeller R, Barreiro P, Jaumé G, Santiago MM, de Miguel GV, Frey U. Standardization procedures for real-time breath analysis by secondary electrospray ionization high-resolution mass spectrometry. Anal Bioanal Chem. 2019;411(19):4883–98.

53. Bruderer T, Gaisl T, Gaugg MT, Nowak N, Streckenbach B, Müller S, Moeller A, Kohler M, Zenobi R. On-line analysis of exhaled breath. Chem Rev. 2019;119(19):10803–28.

54. Lawal O, Ahmed WM, Nijssen TME, Goodacre R, Fowler SJ. Exhaled breath analysis: a review of ‘breath-taking’ methods for off-line analysis. Metabolomics. 2017;13(10):110.

55. Yuan ZC, Li W, Wu L, Huang D, Wu M, Hu B. Solid-phase microextraction fiber in face mask for in vivo sampling and direct mass spectrometry analysis of exhaled breath aerosol. Anal Chem. 2020;92(17):11543–7.

56. Tsubo S, Tsubo Y, Arita M, Bamba T, Fukusaki E. GC/MS based metabolomics: development of a data mining system for metabolite identification by using soft independent modeling of class analogy (SIMCA). BMC Bioinform. 2011;12(1):1–13.

57. Beale DJ, Pinu FR, Kourmenes KA, Poojary MM, Narayana VK, Boughton BA, Kanojia K, Dayalan S, Jones OAH, Dias DA. Review of recent developments in GC–MS approaches to metabolomics-based research. Metabolomics. 2018;14(11):152.

58. Alldhalee WA, Alnuaimi A, Bhagavatula AS. COVID-19 induced hepatitis B virus reactivation: a novel case from the United Arab Emirates. Cureus. 2020;12(6):e8645.

59. Steppert C, Steppert I, Sterlacci W, Bollinger T. Rapid detection of SARS-CoV-2 infection by multicapillary column coupled ion
mobility spectrometry (MCC-IMS) of breath. A proof of concept study. J Breath Res. 2021;15(2):027105.
60. Zheng H, Jin S, Li T, Ying W, Ying B, Chen D, Ning J, Zheng C, Li Y, Li C, Chen C, Li X, Gao H. Metabolomics reveals sex-specific metabolic shifts and predicts the duration from positive to negative in non-severe COVID-19 patients during recovery process. Comput Struct Biotechnol J. 2021;19:1863–73.
61. Lamote K, Janssens E, Schillebeeckx E, Lapperre TS, De Winter BY, van Meerbeek JP. The scent of COVID-19: viral (semi-) volatiles as fast diagnostic biomarkers? J Breath Res. 2020;14(4):042001.
62. Walker HJ, Burrell MM. Could breath analysis by MS could be a solution to rapid, non invasive testing for COVID-19? Bioanalysis. 2020;12(17):1213–7.
63. Mendel J, Frank K, Edlin L, Hall K, Webb D, Mills J, Holness HK, Furton KG, Mills D. Preliminary accuracy of COVID-19 odor detection by canines and HS-SPME-GC-MS using exhaled breath samples. Forensic Sci Int Synerg. 2021;3:100155.
64. Grob NM, Aytekin M, Dweik RA. Biomarkers in exhaled breath condensate: a review of collection, processing and analysis. J Breath Res. 2008;2(3):037004.
65. Zhou B, Xiao JF, Tuli L, Ressom HW. LC-MS-based metabolomics. Mol Biosyst. 2012;8(2):470–81.
66. Chen G, Pramanik BN. Application of LC/MS to proteomics studies: current status and future prospects. Drug Discov Today. 2009;14(9–10):465–71.
67. Bregy L, Nussbaumer-Oehsner Y, Sinues PM-L, García-Gómez D, Suter Y, Gais T, Siebler N, Gaugg MT, Kohler M, Zenobi R. Real-time mass spectrometric identification of metabolites characteristic of chronic obstructive pulmonary disease in exhaled Mass Clin Spectrom. 2018;7:29–35.
68. Sinues PM-L, Meier L, Berchtold C, Ivanov M, Sievi N, Camen G, Kohler M, Zenobi R. Breath analysis in real time by mass spectrometry in chronic obstructive pulmonary disease. Respira. 2014;87(4):301–10.
69. Hanouneh IA, Zein NN, Cikach F, Dababneh L, Grove D, Alkhouri N, Lopez R, Dweik RA. The breathprints in patients with liver disease identify novel breath biomarkers in alcoholic hepatitis. J Clin Gastroenterol. 2014;12(3):516–23.
70. Alkhouri N, Cikach F, Lababneh L, Grove D, Alkhouri N, Lopez R, Dweik RA. The breathprints in patients with liver disease identify novel breath biomarkers in alcoholic hepatitis. J Clin Gastroenterol. 2014;12(3):516–23.
71. Amal H, Leja M, Funka K, Lasina I, Skapars R, Sivins A, Ancans G, Kikuste I, Vanags A, Tolmanis I. Breath testing as potential colorectal cancer screening tool. Int J Cancer. 2016;138(1):229–36.
72. Barash O, Zhang W, Halpern JM, Hua Q-L, Pan Y-Y, Kayal H, Morris PG, Grogan L, Branagan P, Costello RW, De Barra E, Crosshaw B. Exhaled breath concentrations of acetic acid vapour in gastro-esophageal reflux disease. J Breath Res. 2014;8(3):037109.
73. Johnson GR, Morawska L. The mechanism of breath aerosol formation. J Aerosol Med Pulm Drug Deliv. 2009;22(3):229–37.
74. Fumagalli M, Dolcini L, Sala A, Stolk J, Fregonesi L, Ferrari F, Viglio S, Luisetti M, Iadarola P. Proteomic analysis of exhaled breath condensate from single patients with pulmonary emphysema associated to α1-antitrypsin deficiency. J Proteom. 2008;71(2):211–21.
75. Fumagalli M, Ferrari F, Luisetti M, Stolk J, Hiemstra PS, Capuano D, Viglio S, Fregonesi L, Cerveri I, Corana F. Profiling the proteome of exhaled breath condensate in healthy smokers and COPD patients by LC-MS/MS. Int J Mol Sci. 2012;13(11):13894–910.
76. Montesi SB, Mathai SK, Brenner LN, Gershkova IA, Berdysh EV, Tager AM, Shea BS. Docosatetraenoyl LPA is elevated in exhaled breath condensate in idiopathic pulmonary fibrosis. BMC Pulm Med. 2014;14(1):1–7.
77. Cruickshank-Quinn C, Armstrong M, Powell R, Gomez J, Elie M, Reisdorph N. Determining the presence of asthma-related molecules and salivary contamination in exhaled breath condensate. Respir Res. 2017;18(1):1–22.
78. López-Sánchez LM, Jurado-Gámez B, Feu-Collado N, Valverde A, Cañas A, Fernández-Rueda JL, Aranda E, Rodriguez-Ariz A. Exhaled breath condensate biomarkers for the early diagnosis of lung cancer using proteomics. Am J Physiol Lung Cell Mol Physiol. 2017;313(4):L664–76.
79. Gessner C, Dihazi H, Bertschneider S, Hammerschmidt S, Kuhn H, Eschrich K, Keller T, Engellmann L, Sack U, Wirtz H. Presence of cytokertains in exhaled breath condensate of mechanical ventilated patients. Respir Med. 2008;102(2):299–306.
80. Núñez-Navaira L, Maríñas-Pardo LA, Montero-Martínez C. Mass spectrometry analysis of the exhaled breath condensate and proposal of dermcin and S100A9 as possible markers for lung cancer prognosis. Lung. 2019;197(4):523–31.
81. Mutti A, Corradi M, Goldoni M, Vettori MV, Bernard A, Apostoli P. Exhaled metallic elements and serum pneumoproteins in asymptomatic smokers and patients with COPD or asthma. Chest. 2006;129(5):1288–97.
82. Corradi M, Acampa O, Goldoni M, Andreoli R, Milton D, Sama SR, Rosiello R, de Palma G, Apostoli P, Mutti A. Metalic elements in exhaled breath condensate and serum of patients with exacerbation of chronic obstructive pulmonary disease. Metallomics. 2009;1(4):339–45.
83. Lacombe M, Marie-Desvergne C, Combes F, Brais D, Farissier P, Viglio S, Luisetti M, Iadarola P. Proteomic analysis of exhaled breath condensate in patients with idiopathic pulmonary fibrosis. J Breath Res. 2018;12(2):021001.
84. Muccilli V, Saletti R, Cunsolo V, Ho J, Eili G, Conte E, Sichili S, Vancheri C, Foti S. Protein profile of exhaled breath condensate determined by high resolution mass spectrometry. J Pharm Biomed Anal. 2015;105:134–49.
85. Bredberg A, Gobom J, Armstro A-C, Larsson P, Blennow K, Sjövall J, Juhlin D, Gormsen C. Exhaled endogenous particles contain lung proteins. Clin Chem. 2012;58(2):431–40.
86. Rahimpour E, Khounsarbabajari M, Jouyban-Gharamaleki V, Jouyban A. Non-volatile compounds in exhaled breath condensate: review of methodological aspects. Anal Bioanal Chem. 2018;410(25):6411–40.
87. Krejner-Bienias A, Grzelka R, Krupka R, Nejm-Gryz P, Stadnick D, Kobylińska E, Grzelka T. Is the composition of exhaled breath condensate a key to explain the course of COVID-19 in children? Adv Dermatol Allergol. 2020;97395. doi:10.5114/ada.2020.97395.
Hurley K, Gunaratnam C, McElvaney NG, Me OB, Sulaiman I, Morgan RK, Hennessy BT. Use of exhaled breath condensate (EBC) in the diagnosis of SARS-COV-2 (COVID-19). Thorax. 2021;76(1):86–8.

Maier T, Klepel S, Renner U, Kostrzewa M. Fast and reliable MALDI-TOF-MS–based microorganism identification. Nat Methods. 2006;3(4):i–ii.

Dingle TC, Butler-Wu SM. MALDI-TOF mass spectrometry for microorganism identification. Clin Lab Med. 2013;33(3):589–609.

Calderaro A, Arcangeletti M-C, Rodighiero I, Buttrini M, Gorrini C, Motta F, Germini D, Medici M-C, Chezzi C, De Conto F. Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry applied to virus identification. Sci Rep. 2014;4(1):1–10.

Singhal N, Kumar M, Kanaujia PK, Virdi JS. MALDI-TOF mass spectrometry: an emerging technology for microbial identification and diagnosis. Front Microbiol. 2015;6:791.

Kriegsmann J, Casadonte R, Kriegsmann K, Longuespée R, Kriegsmann M. Mass spectrometry in pathology—vision for a future workflow. Pathol Res Pract. 2018;214(8):1057–63.

Xiu L, Zhang C, Wu Z, Peng J. Establishment and application of a universal coronavirus screening method using MALDI-TOF mass spectrometry. Front Microbiol. 2017;8:1510.

Amais RS, Donati GL, Arruda MAZ. ICP-MS and trace element analysis as tools for better understanding medical conditions. Trends Anal Chem. 2020;133:116094.

Sun JK, Zhang WH, Zou L, Liu Y, Li JJ, Kan XH, Dai L, Shi QK, Yuan ST, Yu WK, Xu HY, Gu W, Qi JW. Serum calcium as a biomarker of clinical severity and prognosis in patients with coronavirus disease 2019. Aging. 2020;12(12):11287–95.

Yang C, Ma X, Wu J, Han J, Zheng Z, Duan H, Liu Q, Wu C, Dong Y, Dong L. Low serum calcium and phosphorus and their clinical performance in detecting COVID-19 patients. J Med Virol. 2021;93(3):1639–51.

Fan J, Lian P, Li M, Liu X, Zhou X, Ouyang Z. Ion mobility separation using a dual-LIT miniature mass spectrometer. Anal Chem. 2020;92(3):2573–9.

Wu J, Zhang W, Ouyang Z. On-demand mass spectrometry analysis by miniature mass spectrometer. Anal Chem. 2021;93(15):6003–7.